Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 948.6% | -32.4% | -54.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93% | 90.9% | 96.3% | 96.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -58.2% | -754.7% | -231.3% | -23.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -63.2% | -778.9% | -240.5% | -24.2% |
| EPS Diluted | -3.07 | -4.62 | -2.52 | -0.67 |
| % Growth | 33.5% | -83.3% | -276.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |